News Bristol-Myers Squibb Company

Equities

BMY

US1101221083

Real-time Estimate Cboe BZX Other stock markets 12:34:20 01/06/2024 am IST			5-day change	1st Jan Change
40.94 ^USD	+1.70%		-0.44%	-19.98%

30/05	Bristol-Myers Squibb Says Breyanzi Gets FDA Approval as CAR T Cell Therapy for Mantle Cell Lymphoma	MT
30/05	Bristol Myers: FDA approval for Breyanzi	CF

Summary

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Bristol-Myers Squibb Says Breyanzi Gets FDA Approval as CAR T Cell Therapy for Mantle Cell Lymphoma	30/05	MT
Bristol Myers: FDA approval for Breyanzi	30/05	CF
US FDA allows use of Bristol's cell therapy for rare blood cancer	30/05	RE
U.S. Food and Drug Administration Approves Bristol Myers Squibb’s Breyanzi as a New CAR T Cell Therapy for Relapsed or Refractory Mantle Cell Lymphoma	30/05	BU
Bristol Myers Squibb’s Urothelial Carcinoma Combo Drug Gets EU Commission Approval	29/05	MT
Bristol-Myers Squibb Gains EU Approval for Opdivo Combination Therapy for Urothelial Cancer	29/05	MT
Bristol Myers: new EC approval for Opdivo	29/05	CF
Bristol Myers Squibb Receives European Commission Approval for Opdivo® (nivolumab) in Combination with Cisplatin and Gemcitabine for the First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma	29/05	BU
Bristol Myers Squibb Receives European Commission Approval for Opdivo in Combination with Cisplatin and Gemcitabine	29/05	CI
Prothena to Receive $80 Million From Bristol-Myers Squibb For PRX019 Global License	29/05	MT
Bristol Myers: will present data on schizophrenia	27/05	CF
Bristol Myers: presents over 130 studies at ASCO	27/05	CF
Bristol Myers Squibb to Present Data at ASCO & EHA from More Than 130 Studies Across 25 Diseases Supporting Expansion into New Indications, Demonstrating Long-Term Survival, and Highlighting Novel Modalities and Research Platforms	24/05	BU
Bristol-Myers Squibb Unveils Positive Data for KarXT in Schizophrenia Treatment	23/05	MT
Bristol Myers Squibb to Present Data at the 2024 American Society of Clinical Psychopharmacology Annual Meeting	23/05	BU
Bristol Myers, Sanofi liability in Hawaii Plavix case grows to $916 million	22/05	RE
Bristol Myers Squibb Announces Updated Action Date by the U.S. Food and Drug Administration for Subcutaneous Nivolumab	22/05	AQ
Bristol-Myers Squibb Announces Strategies to Improve Access to Medicines	22/05	MT
Bristol Myers: 10-year strategy for poor countries	22/05	CF
Bristol Myers Squibb Announces 10-Year Strategy to Reach More Patients in Low- and Middle-Income Countries	22/05	BU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

Christopher Boerner, CEO of Bristol-Myers: A pipeline of 16 treatments, with a focus on neuroscience and oncology

January 09, 2024 at 11:36 pm IST